

# **Bazuka Gel**

**PL 00173/0400**

**UKPAR**

## **TABLE OF CONTENTS**

Lay summary	Page 2
Scientific discussion	Page 3
Steps taken for assessment	Page 9
Summary of product characteristics	Page 10
Patient information leaflet	Page 14
Labelling	Page 17

## **BAZUKA GEL**

**PL 00173/0400**

### **LAY SUMMARY**

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a Marketing Authorisation (licence) for the medicinal product Bazuka Gel (product licence number: 00173/0400). This medicine can be bought from pharmacies without a prescription.

Bazuka Gel is a treatment for warts, verrucas, corns and calluses. Warts and verrucas are small excessive growths of skin caused by a type of virus. Corns and calluses are hard, thick pads of skin caused by pressure and friction. Bazuka Gel works by softening the hard skin growth, making it easier to remove with a pumice stone or emery board. It also helps kill the virus that causes warts and verrucas.

Bazuka Gel raised no clinically significant safety concerns and it was, therefore, judged that the benefits of using this product outweigh the risks; hence a Marketing Authorisation has been granted.

**BAZUKA GEL**

**PL 00173/0400**

**SCIENTIFIC DISCUSSION**

**TABLE OF CONTENTS**

Introduction	Page 4
Pharmaceutical assessment	Page 5
Preclinical assessment	Page 6
Clinical assessment (including statistical assessment)	Page 7
Overall conclusions and risk benefit assessment	Page 8

## **INTRODUCTION**

Based on the review of the data on quality, safety and efficacy, the UK granted a marketing authorisation for the medicinal product Bazuka Gel on 25 March 2009.

This is an abridged application for Bazuka Gel submitted under Article 10(c) of EC Directive 2001/83, last paragraph. The applicant claims that this product is identical to Salatac gel (PL 00173/0046), which was licensed to Diomed Developments Limited on 23 February 1989.

No new data were submitted, nor was it necessary for this simple application, as the data are identical to those of the previously granted cross-reference product.

Bazuka Gel is indicated for the topical treatment of warts, verrucas, corns and calluses.

## **PHARMACEUTICAL ASSESSMENT**

### **LETTERS OF ACCESS**

A letter confirming that the applicant is in possession of the dossier for the reference product is provided.

### **DESCRIPTION AND COMPOSITION OF THE DRUG PRODUCT**

Bazuka Gel is a clear colourless collodion-like gel and is presented in a collapsible aluminium tube with a HDPE nozzle/cap

### **ADDITIONAL DATA REQUIREMENTS**

The manufacturing processes, finished product specifications and active ingredient specifications are in line with the reference product and are satisfactory.

### **EXPERT REPORTS**

Satisfactory expert reports in the form of quality, non-clinical and clinical overall summaries are provided, with signed declarations from each expert confirming that the applicant's product is identical to the reference product in all particulars. Expert CVs are also submitted and are acceptable.

### **PRODUCT LITERATURE**

The proposed SPC, PIL and labels are identical to the reference product and are satisfactory. The package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

### **ASSESSOR'S OVERALL CONCLUSIONS**

A product licence may be granted for this product.

## **PRECLINICAL ASSESSMENT**

No new preclinical data have been supplied with these applications and none is required for an application of this type.

## **CLINICAL ASSESSMENT**

### **OVERVIEW**

A statement has been provided confirming that the clinical particulars for Bazuka Gel (PL 00173/0400) are identical to those for the already licensed product; Salatac gel (PL 00173/0046). This is satisfactory.

### **BIOAVAILABILITY AND BIOEQUIVALENCE**

No bioequivalence study has been performed to support these applications and none is needed.

### **PRODUCT LITERATURE**

All product literature is medically satisfactory.

### **ASSESSOR'S OVERALL CONCLUSIONS**

It is recommended that marketing authorisations can be granted.

## **OVERALL CONCLUSION AND RISK BENEFIT ASSESSMENT**

### **QUALITY**

The important quality characteristics of Bazuka Gel are well defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

### **PRECLINICAL**

No new preclinical data were submitted and none are required for applications of this type.

### **EFFICACY**

The efficacy of lactic acid and salicylic acid is well established. The SPCs, PILs and labelling are satisfactory and consistent with those for the cross-reference product.

### **RISK BENEFIT ASSESSMENT**

The quality of the product is acceptable, no significant preclinical or clinical safety concerns were identified, and benefit has been shown to be associated with this type of gel. The risk benefit is therefore considered to be positive.

## **BAZUKA GEL**

**PL 00173/0400**

### **STEPS TAKEN FOR ASSESSMENT**

1	The MHRA received the marketing authorisation applications on 18 July 2007
2	Following standard checks and communication with the applicant the MHRA considered the applications valid on 18 October 2007
3	Following assessment of the application the MHRA requested further information relating to the dossier on 11 September 2008
4	The applicant responded to the MHRA's requests, providing further information on the dossier on 3 December 2008
5	The applications were determined on 25 March 2009

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1 NAME OF THE MEDICINAL PRODUCT**

Bazuka Gel

### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Salicylic Acid 12.0% w/w

Lactic Acid 4.0% w/w

For full list of excipients see section 6.1.

### **3 PHARMACEUTICAL FORM**

Gel

Clear, colourless, collodion-like wart GEL

### **4 CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

For the topical treatment of warts, verrucas, corns and calluses.

#### **4.2 Posology and method of administration**

For adults, children and the elderly. For cutaneous use only.

Bazuka Gel should be applied once daily. The gel should be applied once every night. Treatment can take up to twelve (12) weeks for resistant lesions to disappear, and it is necessary to persevere with the treatment.

1. Every night, soak the affected site in warm water for 2 to 3 minutes.
2. Dry thoroughly with the patient's own towel.
3. Carefully apply one or two drops of the gel to the lesion and allow to dry over its surface. Take care to avoid spreading on to surrounding normal skin. No adhesive plaster is necessary.
4. The following evening, carefully remove and discard the elastic film formed from the previous application, and reapply the gel. Occasionally, if removal of the elastic film proves difficult, carefully reapply the gel directly over it and allow to dry. This should help thicken the film to assist removal. If necessary, such re-application may be made on two or three successive days.
5. Once a week, gently rub away the treated surface using an emery board, as provided, or pumice stone used only for this purpose, before re-applying the gel.
6. The wart, verruca, corn or callus may take up to twelve (12) weeks to disappear and it is important to persevere with the treatment.
7. At the end of treatment, if the elastic film is difficult to remove, it may be allowed to remain on the skin until it sheds.

#### **4.3 Contraindications**

Not to be used on or near the face, intertriginous or anogenital regions, or by diabetics or individuals with impaired peripheral blood circulation.

Not to be used on moles or on any other skin lesions for which the gel is not indicated.

Not to be used in cases of sensitivity to any of the ingredients.

#### **4.4 Special warnings and precautions for use**

Keep away from the eyes, mucous membranes and from cuts and grazes.

The gel should be applied carefully to the wart, verruca, corn or callus only, to avoid possible irritation of surrounding normal skin.

Do not use excessively.

Some mild, transient irritation may be expected, but in cases of more severe or persistent pain/irritation, the treatment should be suspended and/or discontinued. See also Section 4.8.

Avoid inhaling vapour, and keep cap firmly closed when not in use.

Contact with clothing, fabrics, plastics and other materials may cause damage, and should be avoided.

For external use only.

Keep all medicines out of the reach of children.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

None known

#### **4.6 Pregnancy and lactation**

No special precautions

#### **4.7 Effects on ability to drive and use machines**

None known.

#### **4.8 Undesirable effects**

Bazuka Gel may be irritant in certain patients, which in rare instances may appear as a temporary blemish on the skin. See also Section 4.4.

#### **4.9 Overdose**

Any excessive use of the product could cause irritation of the skin. If this occurs, the gel should be used more sparingly or applied less frequently.

### **5 PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

The active ingredients, salicylic acid and lactic acid, are well-established pharmacopoeial substances. In combination, they are routinely used in the treatment of warts, verrucas, corns and calluses for their keratolytic properties. When applied topically, and in high enough concentrations, salicylic acid acts by achieving a slow, painless destruction of the thickened stratum corneum. It softens and destroys the stratum corneum of the affected tissue by reducing the adhesiveness of the corneocytes while causing the cornified epithelium to swell, soften, macerate and finally desquamate. In the treatment of warts, a mild irritant reaction, which may render the virus more prone to immunologic stimulation or response, may add to the mechanical removal of infected cells. The other active ingredient, lactic acid, enhances the availability of the

salicylic acid from the dried collodion, in addition to having antiseptic and caustic properties.

## **5.2 Pharmacokinetic properties**

The product presents 12% salicylic acid and 4% lactic acid in an evaporative collodion-like gel which forms a cohesive and adhesive film on the skin. The formulation is presented in a collapsible aluminium tube fitted with a special applicator nozzle allowing the formulation to be dispensed precisely to the affected areas only. This minimises the spread of the preparation onto the surrounding healthy skin, which could otherwise lead to inflammation, irritation and poor patient compliance.

The film-forming characteristics of the collodion-like gel vehicle also offer distinct advantages in clinical usage. The gel quickly forms a surface film, well before it dries completely, thereby prolonging the period during which the keratolytic solution can properly infiltrate and achieve intimate contact with the surface layers of the thickened stratum corneum.

Furthermore, even when the film appears to have dried completely, the inclusion of the non-evaporative lactic acid ensures that a proportion of the salicylic acid remains in solution within the vehicle, thus permitting continued release of the keratolytic, which may otherwise be entrapped within the collodion-like film.

Systemic absorption of salicylic acid or lactic acid after application of the recommended daily dose of one or two drops of the preparation to small, circumscribed areas is exceedingly unlikely.

## **5.3 Preclinical safety data**

There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SmPC.

# **6 PHARMACEUTICAL PARTICULARS**

## **6.1 List of excipients**

Camphor  
Pyroxylin  
Ethanol (96%)  
Ethyl Acetate

## **6.2 Incompatibilities**

None known.

## **6.3 Shelf life**

36 months in unopened container

## **6.4 Special precautions for storage**

Highly flammable - keep away from flames.  
Do not store above 25°C.

- 6.5 Nature and contents of container**  
5 g and 8 g membrane sealed, epoxy resin-lined, collapsible aluminium tubes with flower pot cap and/or HDPE nozzle applicator and overcap, as appropriate.
- 6.6 Special precautions for disposal**  
Not applicable
- 7 MARKETING AUTHORISATION HOLDER**  
Diomed Developments Limited  
T/A Dermal Laboratories  
Tatmore Place, Gosmore  
Hitchin, Herts, SG4 7QR, UK
- 8 MARKETING AUTHORISATION NUMBER(S)**  
PL 00173/0400
- 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**  
25/03/2009
- 10 DATE OF REVISION OF THE TEXT**  
25/03/2009

**PATIENT INFORMATION LEAFLET**

PACKAGE LEAFLET: INFORMATION FOR THE USER



12.0% w/w salicylic acid, 4.0% w/w lactic acid, gel

Please read all of this leaflet carefully before you start using this product.

Keep this leaflet. You may need to read it again.

Ask your doctor or pharmacist if you need more information or advice.

**In this leaflet:**

- 1. What Bazuka Gel is and what it is used for
- 2. Before you use Bazuka Gel
- 3. How to use Bazuka Gel
- 4. Possible side effects
- 5. How to store Bazuka Gel
- 6. Further information

**1. WHAT BAZUKA GEL IS AND WHAT IT IS USED FOR**

- Bazuka Gel is a treatment for warts, verrucas, corns and calluses.
  - **Warts and verrucas** are small excessive growths of skin caused by a type of virus. Warts often occur on the fingers, or on the back of the hands. You can recognise the common wart by the rough 'cauliflower-like' appearance of the surface. Verrucas occur only on the sole of the foot. They can be painful, and often look like a small white ring of skin with a black dot in the centre. The virus is very infectious. This means that warts and verrucas can grow and spread, particularly if left untreated. The virus can also be transferred from one person to another.
  - **Corns and calluses** are hard, thick pads of skin caused by pressure and friction. They usually occur on the feet due to poorly fitting shoes. They can also occur on the hands.
- Bazuka Gel is suitable for use by **adults, children and the elderly.**
- The **active ingredients** in this product are salicylic acid and lactic acid.
- The active ingredients work by:
  - softening the hard skin growth, making it easier to remove with a pumice stone or emery board;
  - they also help kill the virus that causes warts and verrucas.

**2. BEFORE YOU USE BAZUKA GEL**

**Do not use** Bazuka Gel if you are **allergic** (hypersensitive) to salicylic acid, lactic acid or any of the other ingredients of Bazuka Gel listed in Section 6.

- Do not use the gel anywhere on or near your face, armpits, breasts, bottom or genital (sex) area.
- Do not use the gel on birthmarks, moles, warts with hairs growing from them, or any other spots.
- Do not use the gel if you are diabetic or suffer from poor blood circulation to your hands or feet.

**Take special care** when using this product:

- If you are unsure whether you have a wart, verruca, corn or callus that is suitable for treatment with Bazuka, ask your doctor or pharmacist before starting treatment.
- Apply the gel **carefully**, to the wart, verruca, corn or callus **only**, by squeezing the tube **very gently**:
  - take care **not** to apply the gel to surrounding healthy skin, especially on young children's delicate skin, because this may cause irritation;
  - do not apply excessive amounts of gel.

- Keep the gel away from your eyes, nose, and mouth, and from broken skin, cuts and grazes.
- **Avoid spillage** as this may cause damage to you, your clothing and your possessions (see Section 4):
  - do not fold the tube because this may damage it and make it leak.
- The product is volatile and highly flammable. Do not use it near flames or ignition sources (eg burning cigarettes or anything else that might ignite it).
- Avoid inhaling the vapour from the gel.

**Using other medicines**

This product is not known to affect, or to be affected by any other medicines.

**Pregnancy and breast-feeding**

This product can be used during pregnancy and while breast-feeding. The ingredients have been in widespread use in this and similar preparations for many years, without reports of problems. However, safety trials have not been conducted.

**Driving and using machinery**


Using this product is not known to affect your ability to drive or use machinery.

**3. HOW TO USE BAZUKA GEL**

Use it only on warts, verrucas, corns and calluses on sites for which it is recommended.

**Before you use this tube of gel for the first time, open it as follows:**

- Find a suitable surface, in case of accidental spillage.
- Hold the tube upright, with the cap uppermost and the base resting on a suitable surface.



- Unscrew and remove the combined white and green nozzle/cap assembly from the tube.
- Remove the red collar and throw it away.
- Keep the tube upright for 30 seconds.
- Then, without squeezing or over-gripping the tube, and with it still held upright and away from your face:
  - replace the white and green nozzle/cap assembly onto the screw thread of the tube (taking care to avoid 'cross-threading');
  - tighten the nozzle/cap assembly firmly to pierce the top of the tube;
  - briefly loosen the green cap (to release any slight pressure in the tube) and then retighten.
- Please note that once in place, a small gap will remain between the base of the nozzle/cap and the top of the tube.

Continued overleaf

WD4T2

**To use the gel** (adults, children and the elderly):

Follow these steps **once every day**, usually in the evening. Carry on using the gel in this way until the wart, verruca, corn or callus disappears:

- A. Soak the affected area in warm water for 2 to 3 minutes.
- B. Dry the area thoroughly, using **your own** towel if you have a wart or verruca (this will help stop the infection spreading to other people).
- C. Taking care to avoid squeezing the tube, remove the protective green cap, leaving the white nozzle attached to the tube.



- D. **Carefully** apply a thin coating (one or two drops) of the gel to the top of the wart, verruca, corn or callus **only**:
  - avoid the gel spreading to the surrounding healthy skin;
  - allow the gel to dry for a few minutes to form a small white patch that sticks to the treated area and is water resistant;
  - there is no need to cover the treated area with a sticking plaster;
  - always replace the protective green cap after use.
- E. **The next evening**, carefully peel or pick off the white patch of dried gel from the wart, verruca, corn or callus:
  - apply fresh gel as described above;
  - if removal of the white patch is difficult, carefully re-apply the gel directly over it and leave it to dry. This will thicken the white patch and make it easier to remove.
- F. **Once every week**, before applying fresh gel, **gently** rub the wart, verruca, corn or callus with the emery board provided, or a pumice stone:
  - if you are treating a wart or verruca, **do not let anyone else use the emery board or pumice stone as the infection may spread to them.**
- G. The length of treatment will vary depending on the size and resistance of the wart, verruca, corn or callus:
  - some may go in a relatively short time;
  - some warts and verrucas can require up to 12 weeks treatment before they disappear;
  - it is important that you do not give up on the treatment until the wart, verruca, corn or callus has disappeared (unless irritation occurs, see Section 4 below);
  - if the wart, verruca, corn or callus has not disappeared after twelve weeks of treatment ask your doctor or pharmacist for advice.
- H. At the end of treatment, if the white patch is difficult to remove, you can leave it because it will eventually fall off by itself.

**If the gel accidentally gets onto normal skin**, wipe it off straight away with a tissue, and, if necessary, wash the area.

**If the gel accidentally gets into the eyes or mouth**, it may cause damage. Rinse the eyes or mouth with plenty of water. If rinsing one eye, take care to avoid washing product into the other eye. Then seek urgent hospital attention.

**If you inhale a lot of the vapour from the gel** it may make you feel light-headed. If this happens, get plenty of fresh air.

**If you forget to use Bazuka Gel**

Do not worry if you occasionally forget to use this

product, just carry on using it when you remember. If you have any further questions on the use of this product, ask your doctor or pharmacist.

#### 4. POSSIBLE SIDE EFFECTS

Like all medicines, Bazuka Gel can cause side effects although not everybody gets them:

- While the gel is working you may feel a slight tingling sensation and/or some mild tenderness at the treated area. This is usually temporary, and in rare cases may appear as a temporary blemish on the skin.
- If you mistakenly allow the gel to spread onto and remain in contact with areas of normal skin (see precautions in Section 2), it may cause irritation.
- If you spill the product on your clothes, fabrics, jewellery or metal and polished surfaces it may damage them permanently.
- **Stop using** this product and **tell** your doctor or pharmacist if:
  - you experience unacceptable discomfort or if irritation persists, or;
  - any of the side effects get serious, or you notice any other side effects not mentioned in this leaflet.

#### 5. HOW TO STORE BAZUKA GEL

- Keep out of the reach and sight of children.
- Do not use Bazuka Gel after the expiry date shown on the fold of the tube and on the carton. The expiry date refers to the last day of that month.
- Do not store above 25°C.
- Always replace the cap tightly after use.
- The product is highly flammable. Keep it away from flames or ignition sources.
- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

#### 6. FURTHER INFORMATION ABOUT BAZUKA GEL

**What Bazuka Gel contains:**

The **active ingredients** are salicylic acid (12.0% w/w) and lactic acid (4.0% w/w).

The **other ingredients** are camphor, pyroxylin, ethanol and ethyl acetate.

**What Bazuka Gel looks like and contents of the pack**

The product is a clear colourless gel.

The product is available in a tube containing 5g of gel. The tube has a special applicator nozzle. Each pack also includes an emery board.

**The Marketing Authorisation holder is**

Diomed Developments Ltd, Tatmore Place, Gosmore, Hitchin, Herts, SG4 7QR, UK.

**The Manufacturer is** Pharmasol Ltd, North Way,

Walworth Industrial Estate, Andover, Hampshire, SP10 5AZ, UK.

**The Distributor is** DDD Limited,

94 Rickmansworth Road, Watford, Herts, WD18 7JJ, UK.

**This leaflet was last approved in**

November 2008.

To listen to or request a copy of this leaflet in Braille, large print or audio, please call free of charge: 0800 198 5000 (UK only).

Please be ready to give the following information: Bazuka, 00173/0400

This is a service provided by the Royal National Institute of Blind People (RNIB).

WD4T-2

**LABELLING**

**Label:**

**bazuka**<sup>TM</sup> Gel  
salicylic acid 12% w/w, lactic acid 4% w/w  
for the treatment of verrucas, warts, corns and calluses

FOR EXTERNAL USE ONLY PL 00173/0400 P

**Directions: See patient information leaflet.  
Keep out of the reach and sight of children.**

DO NOT USE IF SEAL ON NOZZLE IS BROKEN

Distributed by DDD Ltd, Watford, WD18 7JJ, UK.

PL Holder Diomed Developments Ltd.

Batch No. and Expiry Date on crimp

5g e

WD1/08/2



**Carton:**

